Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: 11 | History Defined

Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.

Benzinga

UK Government, Eli Lilly Partner To Target Obesity Health Gaps

A new program to improve access to weight management services across the U.K. National Health Service (NHS) could benefit several obese patients.

Benzinga

Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Affirm Holdings Inc (NASDAQ:AFRM) is a buy. “It's at $72, it's going to $100,” he noted.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Government partners with Mounjaro maker to tackle obesity

The £85 million programme will looks at ways for patients to access services more easily.

Evening Standard

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts

A federal appeals court has revived a proposed class action accusing four major drugmakers of conspiring to restrict a government-mandated drug discount program, allegedly driving up costs for safety-net hospitals and clinics serving low-income patients.

Benzinga

Gartner, Eli Lilly, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (August 4-August 8): Are The Others In Your Portfolio?

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?

Benzinga

The Saturday Spread: Using the Neglected Methodology That Wall Street Refuses to Teach

While understanding so-called ‘options math’ can provide interesting context and color, the real alpha generation comes from an entirely different framework.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly

Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats.

MarketBeat

Benzinga Bulls And Bears: AMD, Apple, Eli Lilly — And Wall Street Treads Water

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Benzinga

Trump's Gold Tariffs Shake Markets, Eli Lilly Plunges, Oil Dips On US-Russia Deal, Jobs Miss Fuels Recession Fears — This Week In Economy

The past week has been a rollercoaster ride for the financial markets. From President Donald Trump‘s surprising tariffs on gold to Eli Lilly’s worst day in 25 years, the week was filled with unexpected turns. Let’s dive into the top stories that shaped the week.

Benzinga

My Portfolio, Powered by AI: The Surprising Truth About Automated Investing

When it comes to investing, research is everything. But let’s be honest, it can also be time-consuming and overwhelming, especially if you have never invested...

Saving Advice

Eli Lilly's Orforglipron Data Is Not Disastrous: Analyst

Eli Lilly and Co (NYSE:LLY) released underwhelming data from a Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

Benzinga

Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?

Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone.

MarketBeat

S&P Futures Gain as Investors Weigh Trump’s Fed Governor Pick; Gold Futures Jump on Tariff Report

September S&P 500 E-Mini futures (ESU25) are trending up +0.32% this morning, capping a week dominated by tariff and geopolitical developments, as well as a wave of earnings, with investors weighing U.S. President Donald Trump’s efforts to tighten his grip on the Federal Reserve.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

The Trade Desk, SoundHound AI, Eli Lilly, Block And CrowdStrike: Why These 5 Stocks Are On Investors' Radars Today

The U.S. stock market saw a mixed performance today, with the Nasdaq gaining over 70 points, reflecting a 0.35% increase to 21,242.70. Meanwhile, the SP 500 fell by 0.08% to 6,340, and the Dow Jones Industrial Average experienced a decline of 0.5% to settle at 43,968.64.

Barchart

Stocks Close Mixed after Higher Bond Yields and Tariff News

The S&P 500 Index ($SPX ) (SPY ) Thursday closed down -0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.51%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.32%. September E-mini S&P futures (ESU25 ) fell -0.04%, and September E-mini Nasdaq futures (NQU25...

Kiplinger

Stocks Swing Lower as Eli Lilly, Fortinet Spiral: Stock Market Today

The main indexes finished well off their session highs after a disappointing batch of corporate earnings reports.

The Guardian - UK

Daily pill helps patients lose 12% of body weight in early trial

Results of study suggest orforglipron could be a simpler, cheaper alternative to injections

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Eli Lilly Co. Q2 FY2025 Earnings Transcript

Eli Lilly Co. (NYSE:LLY) reported its second-quarter 2025 financial results ahead of the opening bell on Thursday.

Benzinga

Apple Jumps, Eli Lilly Crashes On Worst Day In 25 Years: What's Moving Markets Thursday?

U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President Donald Trump drove divergent moves in heavyweight names.

Barchart

This Blue-Chip Stock Is Cooking Up a Major Growth Catalyst

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially making it the top choice for patients with Type 2 diabetes.

Barchart

Stocks Turn Mixed After an Early Rally

The S&P 500 Index ($SPX ) (SPY ) today is down -0.04%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.53%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.44%. September E-mini S&P futures (ESU25 ) are down -0.04%, and September E-mini Nasdaq futures...

Euronews

Eli Lilly will seek approval for experimental weight loss pill after promising study

Study participants lost an average of 12.4 per cent of their body weight over 72 weeks.

Benzinga

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ:GPCR) are trading higher.

The Independent UK

‘Shock’ as study reveals how weight-loss pill stacks up against injections

Shares in a pharmaceutical company plummeted after the results were made public

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.